Digital artwork for
production in Blood.
High-resolution files will be required for accepted articles to enter print production. Follow the online uploading
instructions during submission and prepublication. To prepare print-quality figures, see
Figure preparation and sizing
for the final print publication.
back to top
Important Guidelines for Image Preparation
(This set of instructions is adapted with permission from the
Journal of Cell Biology instructions to authors.)
Note that no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. If groupings
of images from different parts of the same gel or microscopic field, or from different gels, fields, or exposures are
used, they must be made explicit by the arrangement of the figure (i.e., by inserting black dividing lines) and in the
text of the figure legend, explaining what steps were taken to produce the final image and for what reason. Adjustments
of brightness, contrast, or color balance are acceptable if they are applied to the whole image and as long as they do
not obscure, eliminate, or misrepresent any information present in the original, including backgrounds. Without background
information, it is not possible to evaluate how much of the original gel is actually shown. Nonlinear adjustments (e.g.,
changes to gamma settings) must be disclosed in the figure legend. The use of special software tools (e.g., erasing,
cloning) available in popular image-editing software is strongly discouraged unless absolutely necessary, and any such
manipulations must be explained in the figure legend.
All images in Figures and Supplemental information from manuscripts accepted for publication are examined for any
indication of improper manipulation or editing. Questions raised by Blood staff will be referred to the Editors,
who may then request the original data from the authors for comparison with the submitted figures. Such manuscripts will
be put on hold and will not be prepublished in Blood First Edition until the matter is satisfactorily resolved.
If the original data cannot be produced, the acceptance of the manuscript may be revoked.
Cases of deliberate misrepresentation of data will result in revocation of acceptance and will be reported to the
corresponding author’s home institution or funding agency.
Figure legends
All legends must begin with a short, descriptive sentence that summarizes the intent and content of the figure. This
sentence should be in boldface. A more detailed explanation of the data contained in the figure
and/or its parts should follow in standard (non-boldface) type.
Whenever possible, the following information should be provided in figure legends regarding the acquisition and
processing of images:
1. Make and model of microscope
2. Type, magnification, and numerical aperture of the objective lenses
3. Temperature
4. Imaging medium
5. Fluorochromes
6. Camera make and model
7. Acquisition software
8. Any subsequent software used for image processing, with details about types of operations involved (e.g., type of
deconvolution, 3D reconstructions, surface or volume rendering, gamma adjustments, etc.).
If some of the information is not available, an explanation needs to be provided.
Tables
Each table should have a brief, specific, descriptive title, giving sufficient explanation to make the data
intelligible without reference to the text. Number all tables and cite in numerical order in the text, using
Arabic numerals.
Display of sequences
Prepare sequences as figures (images), not tables. This will ensure that proper alignment within a sequence is preserved.
back to top
Author membership in the American Society of Hematology is not a prerequisite for submission or publication in Blood
and is not taken into consideration during the peer review process.
All manuscripts must be submitted online through Blood Bench>Press.
Blood does not accept submissions unless they are made online through this site.
If you have not interacted with this Web site before, you must register a new user account using your
primary and desired e-mail address. That, along with your designated password, will be your entry into the
site at all times, so please make sure that your password is easily available to you. The Bench>Press system
is used by many other journals. If you are registered with another journal on Bench>Press, you must contact
the Blood editorial office with the e-mail address with which you are registered to that other site.
The staff will then help you add Blood to the list of Bench>Press journals to which you are registered.
Please note that the same e-mail address and password will apply for all journal Bench>Press sites, including Blood’s.
Before submitting your manuscript online, you should have on hand the following information:
1. Author contact information and individual contributions to authorship
2. Abstract and manuscript files
3. Word counts of abstract and text and a reference count
4. Related Manuscript number(s) if this manuscript was previously submitted (resubmission) or if this submission
is part of a companion group
5. Cover letter to the Editor-in-Chief
6. E-mail addresses of suggested reviewers
7. All coauthors’ most current e-mail addresses
8. Payment information for the submission fee required for all Regular Articles and Brief Reports.
Macintosh users are encouraged to use Safari or Mozilla Firefox instead of Microsoft Internet Explorer to access the
manuscript submission system.
Note that the submission process must be successfully completed before the peer review can begin;
a successful online submission is acknowledged by an e-mail to the corresponding author. In it, the corresponding author
will receive the manuscript number, which needs to be cited in all correspondence, both within and outside Blood
Bench>Press. Please note that you will have 30 days to finish a partial (incomplete) submission of your manuscript.
After 30 days, however, all partial submissions are automatically deleted from the system.
Please note as well that, upon successful submission of a manuscript, all coauthors will receive an automated e-mail
message confirming this submission. If the manuscript is accepted for publication, all coauthors will be contacted again
with instructions for providing their copyright transfer signatures online. Each coauthor will be required to register a user
account in Blood Bench>Press, which will be accessed in order to provide the electronic signature via the Author Area
(see “Manuscript Submission” above). Coauthors’ signatures may be received at any time once a manuscript
is submitted for the first time, but an accepted manuscript will not be prepublished online or otherwise published in Blood
until all signatures are received. See the online copyright transfer section below.
For additional questions regarding the submission process, consult the
authors’ frequently
asked questions regarding manuscript submission. You can also contact the
editorial{at}hematology.org.
back to top
The primary criteria for judging the acceptability of a manuscript are its quality, novelty, and scientific importance.
However, editorial decisions are based not just on technical merit of work, but also on factors such as priority for
publication, presentation of the material, and the relevance to the Journal’s general readership.
At the discretion of the Editors, the manuscript may be returned rapidly, without external peer review, if deemed not
competitive or outside the scope of the journal. All manuscripts are judged in relation to other submissions currently
under consideration.
Manuscripts that have passed an initial screening by the Editors are reviewed by members of the Editorial Board and/or
other experts in the field. The Editors select the reviewers and make the final decision on the manuscript. Referees who
review a manuscript remain unknown to the authors. Every manuscript is treated by the Editors and reviewers as privileged
information, and they are instructed to exclude themselves from review of any manuscript that may involve a conflict of
interest or the appearance of such.
Rebuttals to rejected manuscripts are strongly discouraged, and requests for resubmission of rejected manuscripts are
generally not granted without very significant demonstration of errors in the review or decision process. The majority of
articles are rejected on grounds of insufficient priority or lack of relevance to hematology, not data quality or technical
issues.
back to top
Following initial peer-review, articles judged worthy of further consideration often require revisions, including
additional experimentation. However, articles requiring extensive revisions will be at a disadvantage. Revised manuscript
generally must be received within 3 months of the date on the initial decision e-mail letter, or it will need to be considered
as a new submission, with a separate manuscript number and submission fee. An extension beyond this 3-month time period may on
occasion be granted in order to complete time-consuming new experiments requested by the reviewers; extensions must be requested
from the Associate Editor at least 2 weeks before the 3-month revision deadline expires.
If there are any changes to the manuscript’s authorship since the original submission (such as an addition or deletion
of an author, or a change in the order of authorship), the Change
of Authorship form must be signed by all authors and faxed to the Editorial office to 202-776-0549.
When preparing your revised manuscript for submission, please make sure that all revisions stand out in the text and are
obvious on a black and white printout (e.g., you may use different font size, color or underline). See also
Checklist for Revised
Manuscripts for more information.
back to top
All original research manuscripts accepted through Blood Bench>Press and submitted for Blood First Edition
by the author are prepublished online daily in unedited form (author’s PDF). Blood manuscripts that are accepted and prepublished in
Blood First Edition are considered to be formally published and citable on the date of the article’s appearance on the
Blood First Edition Web site.
They are searchable in Medline, Google Scholar, Yahoo, and other search engines. All prepublished papers will be published in the
final print and online edition of Blood after undergoing copyediting and composition. The authors will have a chance and
are expected to read the page proofs and return them promptly with corrections, in order not to delay the issue production.
Please note that Letters to the Editor, Inside Blood, and Editorials are not prepublished as First Edition articles.
Prior to submitting for First Edition prepublication, the submitting author must carefully review the entire manuscript file,
paying particular attention to list full and accurate names of all authors; include accurate institutional affiliations for each
author; and include all figures, legends, and tables within the uploaded document. Note that figures for First Edition do not need
to be high resolution and may be embedded in the text itself or at the end of the manuscript. Data Supplements are also published
with the First Edition version of the article; they need to be separately uploaded online by following the instructions.
As of Thursday March 27, 2008, Blood requires all authors of newly-submitted manuscripts to electronically provide
their copyright transfer signatures. Upon acceptance of a manuscript, in addition to e-mailed instructions to the corresponding
author for submitting for First Edition, separate correspondence will be sent to all coauthors with instructions for logging on
to Blood Bench>Press individually and providing their electronic signatures. The article will not be prepublished online
until all signatures are received via Blood Bench>Press. Note that manuscripts submitted (or begun in Blood Bench>Press)
prior to Thursday March 27, 2008, will not be included in this requirement, and authors of those manuscripts that are accepted for
publication must sign and fax the Copyright Transfer and Conflict of Interest form
to Blood’s Editorial Office at 202-776-0549.
Blood articles prepublished in First Edition, and articles listed above not prepublished in First Edition subsequently
undergo the standard production processes, including copyediting, composition, and proofreading. The edited article is then
published in its final form in the first available print and online issue of Blood.
A Microsoft Word (.doc) or Rich Text Format (.rtf) file of your accepted manuscript is required to allow the manuscript
to be copyedited and composed. You will be requested to upload the accepted text document during the submission to First
Edition. Please note that publication of your article will be put on hold until you upload a Word or RTF document. You
must make sure that the document you submit is the same as the one accepted. There cannot be ANY content changes from the
final accepted version; however, you should remove any highlighted or red-lined text that may have been inserted to indicate
revisions to the original submission.
back to top
Detailed instructions for submitting digital artwork can be found at Digital artwork for production in Blood.
Blood accepts digital TIFF and EPS images for print. Blood STRONGLY discourages submission of figures as Microsoft PowerPoint (.ppt)
files because they result in much lower quality and resolution figures.
All digital print-quality images need to pass an inspection program, Rapid Inspector, to ensure their suitability for print. You can freely
download the Rapid Inspector software. To deposit your print-ready
image files, you may either upload them alongside your First Edition document or access the Blood FTP site.
Specific instructions are sent in the acceptance letter.
For print publication, lay out figures as compactly as is consistent with conveying the relevant data. Figures will be sized to fit the
smallest possible space, but in order to prevent radical changes in figure content, prepare the figures in one of two sizes: 8.0 cm (1-column width) or,
if necessary, 11.5 cm (1½ column width). Note that these instructions do NOT apply to figures submitted for online review and prepublication.
Cover illustrations are chosen by the Editor-in-Chief. Authors who submit a manuscript are encouraged to include
a color image they consider suitable for the cover of Blood in the supplemental material, with reference to this suggested
cover figure in the cover letter to the Editor-in-Chief. The author must own copyright to the image. The image must be
sharp enough to allow magnification to the full size of the 6½ × 11 in. image area. Add a brief caption explaining the
content of the figure.
Authors of accepted manuscripts will receive electronic page proofs directly from the printer and are responsible for proofreading and checking
the entire article, including tables, figures, and references. Authors should correct only typesetting errors at this stage; more extensive alterations
will result in publication delay and possible additional fees. Page proofs must be returned within 48 hours to avoid delays in publication.
back to top
Please note that the submission fee applies to manuscripts submitted for peer review in Blood; the page charges and the color charges
apply only to the manuscripts accepted for publication in Blood.
Manuscript submission fee
A nonrefundable fee of $50 is due on submission of Regular Articles and Brief Reports. There is no submission fee
for Review Articles, Perspectives, How I Treat, Inside Blood, or Letters to the Editor. If a fee is required,
you will be asked to pay it online at the time of submission, using a credit card. Please note that purchase orders
and bank wire transfers cannot be accepted for the processing fee.
Page charges
Authors of Regular Articles and Brief Reports are required to pay page charges of $60 per printed page to share in the
high costs of publication. Page charges are waived for any type of Review Article, Perspectives, How I Treat, Inside Blood,
or Letters to the Editor.
Color charges
The cost of printing images in color is in part shared with the Blood authors. Color charges are assessed
for authors who submit a color image with a Regular Article, Brief Report, or a Letter to the Editor. Color charges are
waived for color images in a Review Article, Perspectives, How I Treat, or Inside Blood.
Charges to the author are currently assessed at $600 per color figure, even if the figure has multiple panels (A, B,
C, etc.). Color figures included in Supplemental Data, posted online only, do not require payment of the color figure fee.
By submitting color figures at the time of original submission, you are agreeing to pay for color in these figures if the paper
is accepted for publication. It is not acceptable to submit color figures for initial review and subsequent revisions and,
only at the time of acceptance, to change color figures to black and white. You must decide at the time of submission whether you agree
to pay for color in any, or all, of your figures. Please note that the reviewing Editor may decide that, for a given figure, color
is essential for scientific clarity. In such case, the figure will be printed in color and the color charges will be assessed.
Page and color charges are expected to be paid after receipt of an invoice from Cadmus Professional Communications sent to the
corresponding author at the page proof stage.
Reprint requests
Fees for reprints are handled by Cadmus Professional Communications at the page proof stage. Corresponding authors will
receive a reprint price list and order form with their page proof. Reprints must be ordered at the time the page proof are
reviewed. Late orders, especially of reprints with color images, will cost significantly more.
Payment options for reprints and publication fees
It is recommended that international authors pay by credit card (VISA or MasterCard); if they use a check, it must be
drawn from a U.S. bank and made out in U.S. dollars. Domestic (U.S.) authors may use a credit card or pay by check; they will also
have the option to present an Institutional Purchase Order. Make the check out to Cadmus Professional Communications. The
form for Reprints and Publication fees must be returned to the following address:
Cadmus Professional Communications
Reprints and Publication Fees
PO Box 751903
Charlotte, NC 28275-1903
back to top
All authors listed in a manuscript submitted to Blood must have contributed substantially to the work. Upon submission of
the manuscript, the corresponding author must indicate, on the online submission Web site and in the Authorship section
within the manuscript, the specific contribution of each author. This information will be published in the First Edition as well as
in the final print and online versions. Examples of appropriate designations include: designed research, performed research,
contributed vital new reagents or analytical tools, collected data, analyzed and interpreted data, performed statistical
analysis, and/or wrote the manuscript. An author may list more than one type of contribution, and more than one author
may have contributed to the same aspect of the work. The corresponding author takes responsibility for obtaining permission
from all coauthors for the submission of any version of the manuscript and for any changes in authorship.
If a manuscript reports on the results of a clinical trial run by a study group or collaborative clinical trials network,
those members who meet criteria for authorship should be listed individually on the byline; up to 25 individual authors
may be listed. Group members who do not meet the formal authorship criteria listed above but who contributed materially may
be cited in the Acknowledgments section, and if the manuscript is accepted, all group members can be listed in an online supplement.
All individuals share some degree of responsibility for any manuscript they coauthor. Some coauthors have responsibility
for the entire manuscript as an accurate, verifiable report of the research. These include coauthors accountable for the
conception or execution of the research reported in the paper, the integrity and analysis of the data, or the writing of the
manuscript. Coauthors with specific, limited contributions to a paper are responsible for their contributions but may have
only limited responsibility for other results. While not all coauthors may be familiar with all aspects of the research
presented in the manuscript, all coauthors should have in place an appropriate process for reviewing the accuracy of the
reported results.
For more information on this important topic, see the Authorship section in the CSE’s
White Paper on Promoting
Integrity in Scientific Journal Publications.
back to top
All material published in Blood represents the opinions of the authors and does not reflect the opinions of
The American Society of Hematology, the Editors, or the institutions
with which the authors are affiliated.
Authors submitting manuscripts to Blood do so with the understanding that if a manuscript is accepted, the copyright
in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to The American
Society of Hematology and that the corresponding author and all coauthors will be required to sign their
copyright transfer using Blood Bench>Press. This can be done at any time following initial submission of a manuscript
but must be completed before an accepted article is posted to First Edition or otherwise published in the journal.
Blood allows authors to retain a number of nonexclusive rights to their published article. See the
Copyright Transfer and Conflict of Interest form for details.
Do not fill out this form and fax it. Signatures are collected online.
The work of the authors who are U.S. Federal Government employees is not protected by the Copyright Act, and copyright
ownership will not be transferred in these cases. The online form to sign on Blood Bench>Press allows authors to indicate
their status as Federal Government employees.
American Society of Hematology (ASH), the Publisher of Blood, and the Blood Journal are committed to ensuring
the integrity of all their activities. The Conflict of Interest Disclosure policy for Blood contributors requires each author
to disclose all relevant financial and other interests, regardless of amount or value, that might be construed as
resulting in an actual, potential, or apparent conflict in one’s role as contributor to Blood.
At the time of online submission of their manuscript to Blood, authors are required to disclose any potential
financial conflict of interest, which may include one or more of the following: employment; consultancy within the past
two years; ownership interests (including stock options) in a start-up company, the stock of which is not publicly traded;
ownership interest (including stock options but excluding indirect investments through mutual funds and the like) in a
publicly traded company; research funding; honoraria directly received from an entity; paid expert testimony within the
past two years; any other financial relationship (e.g., receiving royalties); membership on another entity’s Board of
Directors or its advisory committees (whether for profit or not for profit).
Examples of conflicts of interest that need to be disclosed include also financial interest in a company whose potential
product was studied in the present work; employment by a company whose potential product was studied in the present work;
and patent related to the work presented in the present work.
If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility
of the corresponding author to review this policy with all authors and to collectively list in the manuscript (under the
Acknowledgment section or in the Authorship section) and in the online submission system ALL pertinent commercial
relationships.
It is important to note that this policy and the disclosure statements will not be regarded as creating a presumption of
impropriety in the existence of financial interests or other relationships of a commercial nature. Instead, Blood’s
purpose is to inform its editors, reviewers, and readers of the existence of financial relationships pertinent to the article
in the interest of the full transparency of the peer review and publication processes.
During the peer review process the conflict(s) of interests will be disclosed only to editors and reviewers, who will keep
them confidential. If the paper is accepted for publication in Blood, all disclosures, including statements of no
conflict of interest, will appear in the First Edition, final print, and final online versions of the article, in the
Authorship section.
All authors are asked to electronically sign their copyright transfer using Blood Bench>Press,
which is available to all authors upon successful initial submission. If accepted, an article will not be prepublished or otherwise
published in the journal until all signatures are received.
To read the ASH Conflict of Interest policy, click here.
back to top
Blood accepts only manuscripts that are original work, no part of which has been submitted for publication elsewhere except as brief abstracts. Authors should take care to exclude overlap and duplication in manuscripts dealing with related materials. Copies of existing manuscripts with potentially overlapping or duplicative material should be submitted together with the manuscript, as Supplemental files, so that the Editors can judge originality of the material and its suitability for publication. Submission of duplicate or partially duplicate publication already published elsewhere will be considered as breach of ethical conduct and will trigger severe consequences.
See also Redundant or Duplicate Publication in Uniform Requirements for Manuscripts Submitted to Biomedical Journals and Definition of Research Misconduct in the CSE’s White Paper on Promoting Integrity in Scientific Journal Publications.
All studies that involve human subjects must abide by the rules of the appropriate Institutional Review Board (or
equivalent organization in foreign countries) of the institution in which the research was conducted and by the tenants of
the World Medical Association’s (most recently revised) Declaration of Helsinki.
Published studies that involve human subjects should not provide subjects’ identifying information (e.g., names, true
initials, recognizable images) unless the information is essential for scientific purposes and the patient (or parent/guardian)
gives written informed consent for publication. If your study requires the appropriate written consent, please submit a
patient-signed copy of the consent to the Editorial Office by fax at 202-776-0549 or via overnight mail to 1900 M St. NW,
Suite 200, Washington, DC 20036. See the Uniform Requirements for
Manuscripts Submitted to Biomedical Journals for further information.
Data sharing
Blood supports the efforts of the National Academy of Sciences to encourage the open sharing of
publication-related data. Blood adheres to the belief that authors should include in their publications the data,
algorithms, or other information that is central or integral to the publication or make it freely and readily accessible;
use public repositories for data whenever possible; and make patented material available under a license for research use.
For more information, see the NAS Web site.
Distribution of reagents
Blood policy requires that any readily renewable resources mentioned in a Journal article and not already obtained
from commercial resources will be made available to all qualified investigators in the field. The policy stems from the
principle that authenticity requires reproducibility. Publication in Blood constitutes a de facto acceptance by
the authors of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and
genomic clones, cell lines, and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro
work reported) of novel protein reagents are also considered transferable.
Although the Editors appreciate that many of the reagents mentioned in Blood may be proprietary or unique, neither
condition is considered adequate grounds for deviation from this policy. Suitable material-transfer agreements can be drawn
up between the provider and the requester, but if a reasonable request is turned down, the corresponding author will be held
accountable. The consequence for continuing noncompliance will be refusal of Blood to publish articles from the corresponding
author for the following three years.
Disclosure of compound structure
Authors must provide the specific chemical structure(s) of synthetic compounds either in the manuscript or through a
Web link to a publicly available source. For natural products, the chemical structure must be similarly provided if it is
known. If it is not known, adequate information on the source and composition must be provided to identify the compound
uniquely.
back to top
Submission of sequences to GenBank
Original DNA sequences reported in Blood must also be submitted to GenBank. Instructions for submission
can be found at GenBank. An accession number must be supplied
parenthetically at a relevant location in text.
Microarray databases
Blood supports the efforts of the Microarray Gene Expression Data Society to standardize the presentation of
microarray data. In compliance with the MGED Society’s
Minimum Information About a Microarray
Experiment (MIAME), the journal requires that authors deposit their microarray data into a public database, such as
Gene Expression Omnibus (GEO) or
ArrayExpress. Authors should also include their
microarray data as a supplement with the initial submission of the manuscript (see
Data Supplements). An accession number must be supplied parenthetically at a relevant location
in text.
In accordance with the guidelines published by the International Committee of Medical Journal Editors (ICMJE)
and the changes to the policy published in an ICMJE
Editorial in June 2007, Blood requires, as a condition of consideration for publication, that all clinical
trials be registered in one of five ICMJE-approved public trials registries (i.e.,
ClinicalTrials.gov,
www.actr.org.au,
www.ISRCTN.org,
www.umin.ac.jp/ctr/index/htm, or
www.trialregister.nl).
Trials must be registered at or before the onset of patient enrollment.
In addition to accepting registration in any of the above five registries, the ICMJE and Blood will
accept registration of clinical trials in any of the primary registers that participate in the
WHO International Clinical Trial Registry Platform (ICTRP).
Registration in a partner register only is insufficient.
The ICMJE and Blood will begin to implement the WHO definition of clinical trials for all trials that begin
enrollment on or after July 1, 2008. This definition states that a clinical trial is “any research study that
prospectively assigns human participants or groups of humans to one or more health-related interventions to
evaluate the effects on health outcomes.”
Following ICMJE, Blood will not consider results posted in the same clinical trials registry in which the
primary registration resides to be previous publication if the results are presented in the form of a brief,
structured (<500 words) abstract or table.
For more information, see ICMJE Uniform
Requirements for Manuscripts Submitted to Biomedical Journals.
back to top
Research with embryonic stem cells should adhere to the guidelines established by the National Academy of Sciences, as published in the
National Academy Press.
The American Society of Hematology supports free access to Blood on the broadest possible basis, although ASH and Blood
cannot adopt or support a publishing model that is not economically sustainable over a long horizon. Blood maintains a 12-month
access embargo to non-subscribers while offering an inexpensive pay-per-view option; however, online content older than 12 months is
free to all. Also, significant sections of each new issue are immediately free-to-all online, including abstracts and tables of contents,
Inside Blood commentaries, How I Treat articles, and 5 clinically relevant research articles or review articles selected by the
Editor-in-Chief. In addition, Blood ensures that patients looking for pertinent information can access any article without charge
by contacting the journal.
Any author (including, but not limited to, those supported by the Wellcome Trust or the Howard Hughes Medical Institute)
wishing immediate open access for their accepted paper may pay an additional Open Access manuscript fee of $2,500. Upon receipt
of payment, Blood will also deposit on behalf of the author the final edition of the published paper into a public repository,
such as PubMed Central.
Blood and the American Society of Hematology (ASH) signed an agreement with the National Institutes of Health (NIH) that creates a
straightforward way for authors to comply with the NIH policy on enhanced access of the public to biomedical research.
This program removes the current burden for NIH-funded authors to submit their manuscripts to
PubMed Central. As a result of ASH’s participation in this program, all Blood authors
who published NIH-funded articles from May, 2005, forward have no obligation to submit manuscripts to the NIH archive because Blood
will do this on their behalf.
Blood manuscripts that are accepted and prepublished in Blood First Edition are considered to be formally published on the date
of the article’s appearance on the Blood First Edition Web site. The site organizes prepublished articles by
posting date and/or by scientific section. Shortly after prepublication in First Edition, the author receives an e-mail notification. There is
no press embargo of an article once it has been prepublished. Any embargo will occur only upon an author’s request and only prior to prepublication.
back to top
